Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENSC vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: ENSC 2 – 3 ANRO (1 Tie) Matrix Metrics: ENSC 4 – 6 ANRO

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ENSC carries a Unified Composite Score of 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin), whereas ANRO carries 45.8/100 (HOLD) at $25.37 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. ANRO 45.8/100 HOLD), ANRO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (+0.0% vs. -15.1% YoY).
  • Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENSC vs ANRO
ENSC NASDAQ
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.37
-4.3% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.86β · 91% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.9%) with fading momentum, RSI 49
RSI-14: 48.5 · SMA20: $25.37 · SMA50: $25.58

6-Pillar Scorecard Institutional Category Breakdown (ENSC 2 – 3 ANRO)

Columns: Metric · ENSC · ANRO
1. Valuation Multiples ENSC
Forward P/E 0.8x N/M
Trailing P/E 0.8x N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) -15.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.5M N/A
Market Cap $7.0M $1.1B
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin -281.3% 0.0%
Net Profit Margin -280.5% 0.0%
Return on Equity (ROE) -1295.1% -46.7%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$9.7M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage -$499,633 Net Debt $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENSC
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 80.4% (8th %ile)
Put/Call OI Skew N/A 20.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENSC (4) vs ANRO (6)
Institutional Metric ENSC ANRO Criterion Row Edge
Market Capitalization
Scale
$7.0M $1.1B Larger Scale ANRO
Trailing P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Forward P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Revenue Growth (YoY)
Growth
-15.1% +0.0% Higher Growth ANRO
Operating Margin (TTM)
Profitability
-281.3% 0.0% Higher Margin ANRO
Net Profit Margin
Profitability
-280.5% 0.0% Higher Margin ANRO
Return on Equity (ROE)
Capital Efficiency
-1295.1% -46.7% Higher ROE ANRO
52-Week Range Position
Momentum
8% ($0–$2) 52% ($13–$37) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
0.98β · 79% Vol 1.86β · 91% Vol Lower Realized Risk ENSC
Unified Institutional Score
Composite Signal
53.4 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$4.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.7M (-$499,633 Net Debt) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +43.83 pp
ENSC: -29.55% · ANRO: +14.28%
3M Horizon ENSC +29.73 pp
ENSC: -0.28% · ANRO: -30.01%
6M Horizon ANRO +6.57 pp
ENSC: +12.99% · ANRO: +19.56%
1Y Horizon ANRO +143.59 pp
ENSC: -80.33% · ANRO: +63.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENSC vs ANRO. Trailing 12-month operating profitability (ENSC -281.3% vs ANRO 0.0%) and valuation multiples (ENSC 0.8x vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ENSC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.5M
Gross MarginN/A
Op. Margin-281.3%
ROE / Fwd P/E-1295.1% · 0.8x
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
61d in phase · OBV DISTRIBUTION
Current IV 80.4%
IV Percentile 8th %ile
Put/Call OI Skew 20.60x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENSC vs ANRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ENSC carries a Unified Composite Score of 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin), whereas ANRO carries 45.8/100 (HOLD) at $25.37 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. ANRO 45.8/100 HOLD), ANRO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (+0.0% vs. -15.1% YoY). Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ENSC posts -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ENSC generates $4.5M in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, ENSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

ENSC screens cheaper on headline valuation multiples. ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENSC (-1295.1% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk). By comparison, ANRO carries 80.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 20.60x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.86β · 91% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.